The p300/CBP inhibitor company

We are developing inobrodib, a new drug to benefit people with cancer

  • 50+

    Epigenetic-related targets

    investigated over time by the CellCentric team

  • 1

    Drug prioritised, advanced

    Inobrodib in the clinic, to treat specific cancers

Inobrodib is a first-in-class oral anti-cancer drug that targets twin tumour drivers, p300/CBP. It is a small molecule, formulated as a capsule taken orally, in Phase I/II clinical trials.

p300/CBP are twin (paralogue) acetyl transferases and gene activating proteins that are known to play an important role in the progression of certain cancers.

Inobrodib is a novel drug which inhibits p300/CBP by binding to the twin proteins’ conserved bromodomain. This impacts the growth of specific types of cancer.

CellCentric’s pioneering drug is in clinical trials to evaluate its effectiveness to treat late-stage prostate cancer, haematological malignancies (blood cancers) and tumours with certain molecular drivers (over-expressing AR or MYC; or with a p300 or CBP mutation). These represent major clinical unmet needs, delivering a new therapy for patients that otherwise have few alternatives.

Tweets by @CellCentric

Follow us

USAN have confirmed a new drug name (stem) for bromodomain inhibitors of p300/CBP. CellCentric’s inobrodib is first in class! pic.twitter.com/mTJpOEhUfH

Great to have many of the core team together; working with our partner clinicians, hospitals, consultants and CROs, to advance inobrodib, our pioneering p300/CBP inhibitor. pic.twitter.com/FS0xWo7zoM